Factors influencing the levothyroxine dose in the hormone replacement therapy of primary hypothyroidism in adults
Open accessThe DOI matches its Crossref record; 163 of the 165 references it cites were found in a registry or an index; 9 of the 132 sources its claims cite were checked for support.
Abstract
Levothyroxine (LT4) is a safe, effective means of hormone replacement therapy for hypothyroidism. Here, we review the pharmaceutical, pathophysiological and behavioural factors influencing the absorption, distribution, metabolism and excretion of LT4. Any factor that alters the state of the epithelium in the stomach or small intestine will reduce and/or slow absorption of LT4; these include ulcerative colitis, coeliac disease, bariatric surgery, Helicobacter pylori infection, food intolerance, gastritis, mineral supplements, dietary fibre, resins, and various drugs. Once in the circulation, LT4 is almost fully bound to plasma proteins. Although free T4 (FT4) and liothyronine concentrations are extensively buffered, it is possible that drug- or disorder-induced changes in plasma proteins levels can modify free hormone levels. The data on the clinical significance of genetic variants in deiodinase genes are contradictory, and wide-scale genotyping of hypothyroid patients is not currently justified. We developed a decision tree for the physician faced with an abnormally high thyroid-stimulating hormone (TSH) level in a patient reporting adequate compliance with the recommended LT4 dose. The physician should review medications, the medical history and the serum FT4 level and check for acute adrenal insufficiency, heterophilic anti-TSH antibodies, antibodies against gastric and intestinal components (gastric parietal cells, endomysium, and tissue transglutaminase 2), and Helicobacter pylori infection. The next step is an LT4 pharmacodynamic absorption test; poor LT4 absorption should prompt a consultation with a gastroenterologist and (depending on the findings) an increase in the LT4 dose level. An in-depth etiological investigation can reveal visceral disorders and, especially, digestive tract disorders.
Overview
CoChat Summary
## TL;DR
This review maps pharmaceutical, pathophysiological, and behavioural factors that alter levothyroxine (LT4) absorption, distribution, metabolism, and excretion, with most effects occurring at the absorption stage. It also gives a practical workup for patients with unexpectedly high TSH on apparently adequate LT4 dosing, emphasizing food/drug interactions, gastrointestinal disease, and LT4 absorption testing.
## Key findings
- The literature search identified 741 potentially relevant publications; 140 were retrieved and 97 were reviewed.
- Around 30% of patients fail to stably achieve the recommended TSH 0.4–4.0 mIU/L with a standard starting LT4 dose, typically 1.5–1.7 µg/kg/day in patients with residual thyroid function.
- In the reviewed studies, the largest and most consistent effects were on absorption: food in the stomach, calcium/iron supplements, PPIs, bile acid sequestrants, sucralfate, fibre, and some gastrointestinal disorders were all reported to reduce LT4 absorption or increase LT4 dose needs.
- Some interventions improved biochemical control or reduced dose requirements, including liquid LT4 in several settings and vitamin C, which in one study lowered TSH by about 70% at the same LT4 dose.
## Methods
- Narrative review based on a PubMed search from January 1, 2000 to April 30, 2021, using combinations of LT4-/thyroid-related terms plus pharmacokinetic terms; only English-language publications and humans-focused clinical study filters were used.
- Abstracts were screened for relevance; full texts were reviewed for eligible studies, and case reports, reviews, and editorials were excluded.
- The authors classified influences on LT4 effectiveness into pharmaceutical, pathophysiological, and behavioural factors, and organized the discussion around ADME: absorption, distribution, metabolism, and excretion.
## Limitations
- The paper states it searched only PubMed and screened only English-language publications.
- Because this is a review, the evidence base is heterogeneous; the text repeatedly notes that findings are inconsistent for some factors, especially time of day of dosing, PPIs, and bariatric surgery.
- Evident from the text: the review relies on studies with varied designs, small samples in some cases, and non-standardized LT4 absorption-test protocols, which limits direct comparison across studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
4 Valid · 2 Not valid · 87 Not checked · 19 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Other reports from both retrospective and prospective observational studies indicate that orally administered liquid and soft-gel formulations of LT4 are associated with higher serum FT4 levels and lower TSH levels than tablet formulations, even when the overall LT4 dose level is the same – perhaps due to the absence of gastric disintegration [ 38 – 44 ].”
What the sources say
- Partly supportedcites [38] Benvenga S, Capodicasa G, Perelli S. l-Thyroxine in an oral liquid or softgel formulation ensures more normal serum levels of free T4 in patients with central hypothyroidism. Front Endocrinol (Lausanne). 2017;8:321. https://doi.org/10.3389/fendo.2017.00321. sourceExperimental — accuracy not yet measured
The Abstract Conclusion (p. n/a) and Results/Figure 4 support the direction and the 'same dose' qualifier: switching CH patients to liquid or softgel l-T4 at the identical daily dose raised serum FT4 by ~20–25% and lowered TSH (0.58±0.26 → 0.17±0.15 mU/l, P=0.0039; 0.62±0.22 → 0.21±0.22 mU/l, P=0.012), described as 'the mirror image of FT4 levels'. What this source does not carry is the claim's unqualified generality: our copy is a 7-patient open prospective case series restricted to central hypothyroidism in patients whose FT4 was consistently below the midnormal range on tablets, chosen because tablet performance was poor, and TSH was only a backing assay behind the fundamental FT4 measurements (Introduction; Patients and Methods). It is neither a retrospective nor a population-wide comparison, so the general association across all hypothyroid patients rests on the other citations in the 38–44 cluster rather than on this paper. (LLM, conf=0.72)
- Not checked yetcites [39] Benvenga S, Di Bari F, Vita R. Undertreated hypothyroidism due to calcium or iron supplementation corrected by oral liquid levothyroxine. Endocrine. 2017;56(1):138–45. https://doi.org/10.1007/s12020-017-1244-2. source
- Disputedcites [40] Fallahi P, Ferrari SM, Antonelli A. Oral L-thyroxine liquid versus tablet in patients with hypothyroidism without malabsorption: A prospective study. Endocrine. 2016;52(3):597–601. https://doi.org/10.1007/s12020-015-0836-y. sourceExperimental — accuracy not yet measured
Fallahi et al. (2016) support only half of the attributed claim: after switching hypothyroid patients without malabsorption from L-T4 tablets to liquid L-T4 'at the same dosage', TSH fell significantly (Abstract, p. 2; Results, p. 5; Fig. 1 legend, p. 14). However, the same passages state the contrary on the FT4 component — 'FT4 and FT3 levels were not significantly changed' (Results, p. 5; Abstract, p. 2) — so this study does not show higher serum FT4 with the liquid formulation. Our copy also limits the comparison to liquid L-T4 (Tirosint fiala monouso, Patients and methods, p. 4); soft-gel is mentioned only as an available formulation in the Introduction (p. 3) and was not studied, and the Discussion (p. 6) attributes the TSH decline to hypothesized increased absorption whose 'involved mechanisms need to be further studied'. (LLM, conf=0.75)
Checked by a reasoning model — may be wrong.
- Not checked yetcites [41] Brancato D, et al. Comparison of TSH levels with liquid formulation versus tablet formulations of levothyroxine in the treatment of adult hypothyroidism. Endocr Pract. 2014;20(7):657–62. https://doi.org/10.4158/EP13418.OR. source
- Partly supportedcites [42] Trimboli P, et al. Thyroxine treatment with softgel capsule formulation: Usefulness in hypothyroid patients without malabsorption. Front Endocrinol (Lausanne). 2018;9:118. https://doi.org/10.3389/fendo.2018.00118. sourceExperimental — accuracy not yet measured
Trimboli et al. (2018) support the TSH half of the claim: switching hypothyroid patients without malabsorption from tablet to softgel LT4 at unchanged dose significantly lowered TSH (median 1.90 vs 3.33 mIU/L, p = 0.0039; Abstract Results, Results p. n/a), and the Introduction (p. n/a) notes a meta-analysis showing lower serum TSH when switching to liquid LT4 at unchanged dose. However, the 'higher serum FT4 levels' part is not supported by this paper: the Background states TSH was used as the proxy of LT4 bioavailability, and the Discussion limitations state that 'free-T4 and free-T3 values were not available for all patients because of the use of reflex TSH in clinical practice,' with FT4 merely reported as within the normal range. Thus the FT4 component of the attributed claim, and the joint liquid-plus-softgel framing, exceed what this source reports. (LLM, conf=0.85)
- Not checked yetcites [43] Ribichini D, et al. Tablet and oral liquid L-thyroxine formulation in the treatment of naive hypothyroid patients with Helicobacter pylori infection. Endocrine. 2017;57(3):394–401. https://doi.org/10.1007/s12020-016-1167-3. source
- Not checked yetcites [44] Ferrara R, et al. Treatment pattern and frequency of serum TSH measurement in users of different levothyroxine formulations: A population-based study during the years 2009–2015. Endocrine. 2017;58(1):143–52. https://doi.org/10.1007/s12020-017-1242-4. source
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Bach-Huynh et al. three-period crossover study of 65 LT4-treated stable hypothyroid patients found that non-fasting LT4 administration was associated with higher and more variable serum TSH concentrations [ 33 ].”
What the sources say
- Partly supportedcites [33] Bach-Huynh TG, et al. Timing of levothyroxine administration affects serum thyrotropin concentration. J Clin Endocrinol Metab. 2009;94(10):3905–12. https://doi.org/10.1210/jc.2009-0860. sourceExperimental — accuracy not yet measured
The Abstract describes a three-period crossover study, and the Discussion reports higher and more variable TSH under nonfasting regimens. However, the Results (Participant characteristics) say that of the 65 patients who completed the study, 42 had hypothyroidism and 23 had thyroid cancer; the source does not describe all 65 as hypothyroid patients. (LLM, conf=0.88)
plainstates an associationn = 65- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“around 30% of patients fail to stably achieve the recommended serum level of thyroid-stimulating hormone (TSH; between 0.4 and 4.0 mIU/L, according to the American Thyroid Association guidelines) with a standard, body-weight-based starting dose of LT4 (typically 1.5 to 1.7 µg/kg/day in patients with residual endogenous thyroid function, such as those with auto-immune thyroiditis) [ 2 , 10 – 12 ].”
What the sources say
- Partly supportedcites [2] Jonklaas J, et al. Guidelines for the treatment of hypothyroidism: Prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670–751. https://doi.org/10.1089/thy.2014.0028. sourceExperimental — accuracy not yet measured
The Discussion of the clinical literature (page not available in our copy) supports normalizing TSH and considering body weight and residual thyroid function when determining LT4 dose. It gives 1.6–1.8 μg/kg for patients with minimal endogenous thyroid function, not the claimed 1.5–1.7 μg/kg for patients with residual function. The passages found do not establish the 30% failure rate or specify a universal TSH target of 0.4–4.0 mIU/L; they discuss reference ranges and age-specific targets instead. (LLM, conf=0.86)
- Not checked yetcites [10] Okosieme OE, et al. Adequacy of thyroid hormone replacement in a general population. QJM. 2011;104(5):395–401. https://doi.org/10.1093/qjmed/hcq222. source
- Not checked yetcites [11] Zaborek NA, et al. The optimal dosing scheme for levothyroxine after thyroidectomy: A comprehensive comparison and evaluation. Surgery. 2019;165(1):92–8. https://doi.org/10.1016/j.surg.2018.04.097. source
- Partly supportedcites [12] Virili C, et al. Gastrointestinal malabsorption of thyroxine. Endocr Rev. 2019;40(1):118–36. https://doi.org/10.1210/er.2018-00168. sourceExperimental — accuracy not yet measured
The Introduction reports that 20%–50% of patients do not achieve a complete biochemical and/or clinical response to a reference thyroxine dose, and gives a consensus dose of 1.6–1.8 µg/kg/day. It does not specify that around 30% fail to stably maintain TSH at 0.4–4.0 mIU/L. The section “How oral thyroxine is ingested” describes the 1.6–1.8 µg/kg/day recommendation for adults with minimal, rather than residual, endogenous thyroid function. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Taking LT4 with grapefruit juice was associated with statistically significant decreases (of around 10%) in the peak T4 concentration and the AUC for T4.”
What the sources say
- Supportedcites [82] Lilja JJ, Laitinen K, Neuvonen PJ. Effects of grapefruit juice on the absorption of levothyroxine. Br J Clin Pharmacol. 2005;60(3):337–41. https://doi.org/10.1111/j.1365-2125.2005.02433.x. source
The Results report an 11% decrease in the maximal increase in T4 concentration (P < 0.01) and a 13% decrease in the incremental T4 AUC over 0–4 hours (P < 0.05). The 0–6-hour AUC also decreased by 9%, but that result was not statistically significant; the claim is supported by the 0–4-hour measure. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Furthermore, a high proportion of LT4-treated patients ingest medications, foodstuffs and food supplements that selectively or specifically reduce the intestinal absorption of LT4.”
What the sources say
- Supportedcites [48] McMillan M, et al. Comorbidities, concomitant medications, and diet as factors affecting levothyroxine therapy: Results of the CONTROL surveillance project. Drugs R D. 2016;16(1):53–68. https://doi.org/10.1007/s40268-015-0116-6. source
The Results section reports that 51.8% of levothyroxine-treated patients frequently took supplements known to cause malabsorption, and 68.0% frequently consumed foods or beverages known to do so. It also reports substantial use of medications that could adversely affect levothyroxine absorption. These findings support the claim that a high proportion ingest such products. (LLM, conf=0.91)
- Partly supportedcites [61] Benvenga S, et al. A minimum of two years of undertreated primary hypothyroidism, as a result of drug-induced malabsorption of l-thyroxine, may have metabolic and cardiovascular consequences. J Clin Transl Endocrinol. 2019;16: 100189. https://doi.org/10.1016/j.jcte.2019.100189. sourceExperimental — accuracy not yet measured
The Patients section reports that 391 of 730 tablet LT4 users had taken drugs known to inhibit LT4 intestinal absorption; the Discussion describes this as approximately one in two. The paper supports the claim about medications, but the cited passages do not establish a high proportion ingesting interfering foodstuffs or food supplements. (LLM, conf=0.88)
- Not checked yetcites [62] Abu Hashim H, Foda O, Ghayaty E. Lactoferrin or ferrous salts for iron deficiency anemia in pregnancy: A meta-analysis of randomized trials. Eur J Obstet Gynecol Reprod Biol. 2017;219:45–52. https://doi.org/10.1016/j.ejogrb.2017.10.003. source
- Not checked yetcites [63] Trifiro G, et al. Drug interactions with levothyroxine therapy in patients with hypothyroidism: Observational study in general practice. Clin Drug Investig. 2015;35(3):187–95. https://doi.org/10.1007/s40261-015-0271-0. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
51 more claims
Create a free account to see all 112 claims and to verify the 123 references still open.
- Probably not a substantial claim. 34
- It may state two separate claims as one. 41
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Natural juices are instead believed to increase pH in the stomach and reduce LT4 bioavailability (51).”
From ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism (2025) · cites this paper as [51]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several different variations of thyroid pathophysiology have been described in the elderly (92, 93). Reduced lean body mass, reduced T4 absorption and outer ring deiodination as well as the presence of comorbidities and the use of drugs are among them (14, 42, 51).”
From ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism (2025) · cites this paper as [51]
Experimental — accuracy not yet measuredIn the citing paper
“Crohn's disease might potentially elevate LT4 requirements; however, there is limited evidence regarding this.66”
From Refractory hypothyroidism: unraveling the complexities of diagnosis and management (2023) · cites this paper as [66]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Our literature search did not identify any publications on interactions between bacterial or viral infections and the effectiveness of LT4.”
“the administration of a liquid LT4 formulation in patients with hypothyroidism and an ongoing Helicobacter pylori infection was associated with a significantly greater fall in TSH levels, relative to administration of a tablet formulation [ 43 ].”
Citations
Cites
Hollowell, J. G., Staehling, N. W., Flanders, W. D., Hannon, W. H., Gunter, E. W., Spencer, C. A., & Braverman, L. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.2.489 · Cited by 4,279
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928
Bianco, A. C., Salvatore, D., Gereben, B., Berry, M. J., & Larsen, P. R. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.1.0455 · Cited by 1,853 · cited 1×
“Primarily, deiodination of T4’s outer ring by type 2 deiodinase (DIO2) gives liothyronine (L-tri-iodothyronine or T3, the main biologically active metabolite), and deiodination of the inner ring by type 1 or type 3 deiodinases (DIO1 or DIO3) gives the biologically inactive reverse T3 (rT3) [21].”
BackgroundThe Incidence and Prevalence of Thyroid Dysfunction in Europe: A Meta-Analysis
Garmendia Madariaga, A., Santos Palacios, S., Guillén-Grima, F., & Galofré, J. C. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2409 · Cited by 800
Oxidative Stress in Cardiovascular Diseases
Dubois-Deruy, E., Peugnet, V., Turkieh, A., & Pinet, F. (2020) · Antioxidants · doi:10.3390/antiox9090864 · Cited by 646
Alexander, E. K., Marqusee, E., Lawrence, J., Jarolim, P., Fischer, G. A., & Larsen, P. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040079 · Cited by 633
Intestinal Drug Transporter Expression and the Impact of Grapefruit Juice in Humans
Glaeser, H., Bailey, D. G., Dresser, G. K., Gregor, J. C., Schwarz, U. I., McGrath, J. S., Jolicoeur, E., Lee, W., Leake, B. F., Tirona, R. G., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100056 · Cited by 407 · cited 1×
“1 3 juice effect” on the absorption of some drugs is due to inhibition of the organic anion transporting polypeptide 1A2 (OATP1A2) transporter in the intestinal mucosa, as has also been suggested for the drug ciprofloxacin [83, 84].”
BackgroundAoki, Y., Belin, R. M., Clickner, R., Jeffries, R., Phillips, L., & Mahaffey, K. R. (2007) · Thyroid · doi:10.1089/thy.2006.0235 · Cited by 390
Lenti, M. V., Rugge, M., Lahner, E., Miceli, E., Toh, B.-H., Genta, R. M., De Block, C., Hershko, C., & Di Sabatino, A. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0187-8 · Cited by 350
Thyroid hormone replacement for subclinical hypothyroidism
Villar, H. C. C. E., Saconato, H., Valente, O., & Atallah, Á. N. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003419.pub2 · Cited by 329
Research works printed but not linked: 1
- Medicines optimisation: The safe and effective use of medicines to enable the best possible outcomes. Accessed at 2015. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26180890.
Cited by
Diagnostic and therapeutic value of human serpin family proteins
Janciauskiene, S. M., Lechowicz, U., Pelc, M., Olejnicka, B. T., & Chorostowska‐Wynimko, J. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116618 · Cited by 48
Centanni, M., Duntas, L., Feldt-Rasmussen, U., Koehrle, J., Peeters, R. P., Razvi, S., Trimboli, P., & Virili, C. (2025) · European Thyroid Journal · doi:10.1530/etj-25-0123 · Cited by 38
“Reduced lean body mass, reduced T4 absorption and outer ring deiodination as well as the presence of comorbidities and the use of drugs are among them (14, 42, 51).”
InfluentialSelf-citationThe impact of weight loss interventions on thyroid function: a systematic review and meta-analysis
Nayak, S. S., Hashemi, S. M., Patel, M., Shafi, N., Biswas, P., Javankiani, S., Jaladi, P., Patil, S. B., Rashid, R., Amini‐Salehi, E., et al. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003428 · Cited by 21
“Conversely, weight loss might require a reduction in dosage to avoid symptoms of hyperthyroidism [ 15 ] .”
Ouyang, Q., Xu, Y., Ban, Y., Li, J., Cai, Y., Wu, B., Hao, Y., Sun, Z., Zhang, M., Wang, M., et al. (2023) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-023-10068-4 · Cited by 21
The use of levothyroxine absorption tests in clinical practice
Caron, P., & Declèves, X. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad132 · Cited by 18
Self-citation
Metadata
- Authors
- Caron, P., Grunenwald, S., Persani, L., Borson-Chazot, F., Leroy, R., & Duntas, L.
- Affiliations
- Centre Hospitalier Universitaire de Toulouse (FR)
- University of Milan (IT)
- National and Kapodistrian University of Athens (GR)
- Corresponding author
- Caron, Philippe
- Venue
- Reviews in Endocrine and Metabolic Disorders
- Published
- 2021-10-20
- Volume
- 23
- Issue
- 3
- Pages
- 463-483
- ISSN
- 1389-9155 (ISSN-L)
- 1573-2606
- PMC
- PMC8528480
- OpenAlex
- W3206952166
- Cited by
- 53
- References
- 165
- Citations by year
- 2026: 12 · 2025: 14 · 2024: 12 · 2023: 12 · 2022: 3
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Reviews in Endocrine and Metabolic Disorders (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, cc-by)
- Funders
- merck kgaa
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- levothyroxine, primary hypothyroidism, hormone replacement therapy, levothyroxine dose, drug interactions, gastrointestinal diseases, gastric acid secretion, intestinal absorption, free thyroxine, thyroid-stimulating hormone, Helicobacter pylori infection, celiac disease, bariatric surgery, pharmacokinetics, pharmacodynamics
- MeSH terms
- Adult, Humans, Hypothyroidism, Thyrotropin, Thyroxine, Helicobacter pylori, Helicobacter Infections, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Factors influencing the levothyroxine dose in the hormone replacement therapy of primary hypothyroidism in adults. https://app.cochat.ai/papers/10.1007/s11154-021-09691-9
- The paper
- Caron, P., Grunenwald, S., Persani, L., Borson-Chazot, F., Leroy, R., & Duntas, L. (2022). Factors influencing the levothyroxine dose in the hormone replacement therapy of primary hypothyroidism in adults. Reviews in Endocrine and Metabolic Disorders. https://doi.org/10.1007/s11154-021-09691-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.